Akero Therapeutics, Inc.
AKRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,868 | $1,227 | $2,136 | $737 |
| - Cash | $340 | $234 | $250 | $150 |
| + Debt | $36 | $26 | $11 | $2 |
| Enterprise Value | $1,564 | $1,020 | $1,898 | $588 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$247 | -$149 | -$111 | -$101 |
| % Margin | – | – | – | – |
| Net Income | -$252 | -$152 | -$112 | -$101 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.75 | -2.89 | -2.87 | -2.89 |
| % Growth | -29.8% | -0.7% | 0.7% | – |
| Operating Cash Flow | -$230 | -$145 | -$93 | -$80 |
| Capital Expenditures | -$1 | $0 | $0 | $0 |
| Free Cash Flow | -$231 | -$145 | -$93 | -$80 |